[Efficacy of @entity901 plus @entity1487 /leucovorin @entity460 combined with concurrent radiotherapy for local advanced XXXX ].

@entity901 @entity1 @entity851 @entity137 @entity5 @entity15114 @entity1503 @entity74 @entity460 @entity204 @entity356 @entity1487
OBJECTIVE: To evaluate the efficacy of r @entity901 plus @entity1487 /leucovorin @entity460 (LV) combined with concurrent radiotherapy in the treatment of local advanced @entity356 . METHODS: 83 @entity1 with local advanced @entity356 were randomized into 2 groups. Group I (n = 40) underwent irradiation at the dose of 40 - 45 Gy 5 times a week on the @entity5 and the lymph nodes with the size > or = 10 mm in @entity851 , and receiving intravenous drip of @entity15114 85 mg/m2 for 2 h, intravenous injection of LV 200 mg/m2, and then intravenous injection of 5-fu 300 mg/m2, followed by continuous intravenous infusion of 5-fu 500 mg/m2, for 22 h, with 2 weeks as a cycle. Three cycles of chemotherapy were given during the radiotherapy. Then operative evaluation was conducted. Those resectable underwent operation and then 3 cycles of adjuvant chemotherapy. Those un-resectable underwent continuous 3 cycles of chemotherapy. Group II (n = 43) received only chemotherapy. The treatment was repeated until disease progression or prohibitive @entity137 . RESULTS: 38 @entity1 were evaluated in Group I, the result showed complete remission (CR) in 4 @entity1 (10.5%), partial remission (PR) in 23(60.5%), no-change (NC) in 7(18.4%), @entity74 ( @entity74 ) in 5(13.2%), with the remission rate (RR) of 71% (27/40). 42 @entity1 were evaluated in Group II, the result showed CR in 3 @entity1 (7.14%), PR in 16(14.3%), NC in 13(30.9%), and @entity74 in 9(26.2%)with the RR of 45% (19/43). The resection rates of Groups I and II were 32.5% and 27.9% respectively (P = 0.649). The R0 resection rates of Groups I and II were 77.8% and 57.1% respectively (P = 0.161). The mean survival times of the resectable @entity1 in Groups I and II were 45 months and 28 months respectively, and the 2-year overall survival (OS) of the resectable @entity1 in Groups I and II were 65.8% and 56.3% respectively (P = 0.371). The mean survival times of the un-resectable @entity1 in Groups I and II were 14 months and 9 months respectively, and the 2-year OS rates of the un-resectable @entity1 in Groups I and II were 28.3% and 20.7% respectively (P = 0.017). The toxic and adverse effects included @entity1503 . There was no treatment-related @entity204 . CONCLUSION: Radiotherapy combined with concurrent chemotherapy may be an effective and well-tolerated regimen in @entity1 with advanced and metastatic @entity356 .
